European Medicines Agency

News and Video Search Results

News coverage

JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension

GlobeNewswire 26 Apr 2024

*Ad hoc announcement pursuant to Art. 53 LR*

· Idorsia receives a positive opinion from the Committee for Medicinal..

Guerbet : Q1 2024 revenue.
GlobeNewswire 25 Apr 2024
Medical Imaging Devices Market: Today and Over the Next 10 Years (2024-2034)
GlobeNewswire 25 Apr 2024
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
GlobeNewswire 25 Apr 2024
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
GlobeNewswire 25 Apr 2024

0 shares 1 views

You might like

European Medicines Agency media coverage

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab

GlobeNewswire 25 Apr 2024

SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877;..

SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire 24 Apr 2024
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
GlobeNewswire 24 Apr 2024
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
GlobeNewswire 24 Apr 2024
Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency
Accesswire 23 Apr 2024

Advertisement

More coverage

Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies

Business Wire 23 Apr 2024

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company,..